ADMA Biologics CEO to Highlight Innovations
ADMA Biologics, Inc. (NASDAQ: ADMA), a leading biopharmaceutical company specializing in innovative biologics, is gearing up to participate in a significant event that promises to shed light on its advancements and future plans. Adam Grossman, the President and CEO, will be featuring at the prestigious Raymond James Institutional Investor Conference. This engaging fireside chat is scheduled for 11:35 a.m. ET, allowing investors to gain deeper insights into the company's direction and priorities.
Listening In: What to Expect
The presentation will be accessible via a live audio webcast, conveniently located within the investor section of ADMA's official website. Following the event, an archived version will also be released online for those who wish to revisit the insightful discussions shared during the chat. This initiative underlines ADMA's commitment to transparency and keeping its investors well-informed.
Company Overview: ADMA Biologics
ADMA Biologics focuses on the manufacture and commercialization of specialty biologics aimed at immunocompromised patients and those susceptible to specific infectious diseases. The company is recognized for its exceptional standards in the field of biopharmaceuticals. Currently, it offers three FDA-approved plasma-derived biologics: ASCENIV™ for humoral immunodeficiency, BIVIGAM® for primary immunodeficiency, and NABI-HB® to combat hepatitis B. These offerings underscore ADMA's extensive expertise in producing vital therapeutic products.
Commitment to Quality and Safety
Manufactured at its FDA-licensed facility in Boca Raton, Florida, ADMA takes great pride in maintaining high safety and quality standards in its products. The company also extends its operations through ADMA BioCenters, which sources plasma necessary for its product lines, ensuring that all processes meet FDA regulations and standards.
Mission Statement and Goals
ADMA's mission revolves around producing and marketing specialized biologics that address the healthcare needs of niche patient populations at risk for various infections. By targeting specific groups that may suffer from underlying immune deficiencies, the company aims to significantly enhance public health outcomes. As part of their strategy, ADMA is also actively involved in research and development, continuously striving to expand its product portfolio and improve existing offerings.
Future Directions
As we look to the future, ADMA Biologics has clear goals to expand its market footprint and innovate within the biopharmaceutical landscape. The upcoming conference presentation is an excellent opportunity to share these aspirations with stakeholders and gather feedback to refine their strategies moving forward.
Investor Relations
For those interested in additional details or investor communications, ADMA has made it convenient to reach out. The Investor Relations team, based at Argot Partners, welcomes inquiries at 212-600-1902 or via email at ADMA@argotpartners.com. This open communication channel demonstrates ADMA's commitment to investor engagement and support.
Frequently Asked Questions
What will the CEO discuss at the Raymond James Conference?
The CEO will cover recent innovations, company strategies, and insights into ADMA's operations.
Where can I listen to the live webcast?
The webcast will be available on ADMA's official website under the investor section.
What products does ADMA Biologics offer?
ADMA offers three FDA-approved biologics: ASCENIV™, BIVIGAM®, and NABI-HB®.
What is the mission of ADMA Biologics?
ADMA’s mission focuses on manufacturing and marketing specialty biologics for immunocompromised patients.
How can I contact Investor Relations for more information?
You can contact Argot Partners at 212-600-1902 or email ADMA@argotpartners.com.
